HomeGrants › FOR-FD-25-006

Forecasted

Studies Addressing Rare Neurodegenerative Diseases including ALS

Federal funding opportunity FOR-FD-25-006 from Food and Drug Administration.

View forecast on Grants.gov →Forecasted — not yet open

Posted
August 14, 2024
Closes
See announcement
Expected awards
10
Cost sharing
No
Instrument
Grant
Assistance listing
93.103
Category
Agriculture, Consumer Protection, Food and Nutrition

Program funding history

Awards made under Assistance Listing 93.103 across FY2024–FY2026, from public federal spending records.

FY2024 obligated
$250.8M
FY2025 obligated
$213M
FY2026 (to date) obligated
$15M
Awards in window
911

Top recipients: The Critical Path Institute, National Environmental Health Association, Association of Food & Drug Officials, The Medical Device Innovation Consortium, Duke University

Source: USAspending.gov · refreshed July 2026

Synopsis

The purpose of this funding opportunity announcement (FOA) is to support studies that advance medical product development of interventions intended to prevent, diagnose, mitigate, treat, or cure ALS and other rare neurodegenerative diseases in adults and children. Through the support of these studies, FDA expects to address critical knowledge gaps, exert a significant impact on rare neurodegenerative diseases, and to inform current or future product development.  

Who can apply

How to apply

Applications go through the official government listing. Grants Radar links you straight to the source.

View on Grants.gov

Agency contact: Terrin Brown Grantor · terrin.brown@fda.hhs.gov · 2404027610

Get grants like this every Tuesday — free

One email a week: the biggest new federal grants and what’s closing soon. Unsubscribe in one click.

The free edition carries one clearly labeled sponsor slot. No spam, ever. Privacy

Similar grants

Never miss a funding deadline again

Grants Radar sends AI-enriched alerts on federal grants and contracts matched to what you do. Founding seats are limited and locked for life.

Get funding alerts